Mass spectrometry-based proteomic discovery of prognostic biomarkers in adrenal cortical carcinoma

Han Na Jang, Sun Joon Moon, Kyeong Cheon Jung, Sang Wan Kim, Hyeyoon Kim, Dohyun Han, Jung Hee Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We performed the liquid chromatography–tandem mass spectrometry (LC–MS/MS) using formalin-fixed paraffin-embedded (FFPE) tissues of 45 adrenal tumors. Then, we selected 117 differentially expressed proteins (DEPs) among tumors with different stages using the machine learning algorithm. Next, we conducted a survival analysis to assess whether the levels of DEPs were related to survival. Among 117 DEPs, HNRNPA1, C8A, CHMP6, LTBP4, SPR, NCEH1, MRPS23, POLDIP2, and WBSCR16 were significantly correlated with the survival of ACC. In age-and stage-adjusted Cox proportional hazard regression models, only HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 expression remained significant. These five proteins were also validated in TCGA data as the prognostic biomarkers. In this study, we found that HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 were protein biomarkers for predicting the prognosis of ACC.

Original languageEnglish
Article number3890
JournalCancers
Volume13
Issue number15
DOIs
StatePublished - 1 Aug 2021

Keywords

  • Adrenal cortical carcinoma
  • HNRNPA1
  • Mass spectrometry
  • Prognosis
  • Proteomics

Fingerprint

Dive into the research topics of 'Mass spectrometry-based proteomic discovery of prognostic biomarkers in adrenal cortical carcinoma'. Together they form a unique fingerprint.

Cite this